Research ExplorerPublicationsTreatment landscape of advanced breast cancer patients with ...

Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry

Standard

Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry. / Hartkopf, Andreas D; Huober, Jens; Volz, Bernhard; Nabieva, Naiba; Taran, Florin-Andrei; Schwitulla, Judith; Overkamp, Friedrich; Kolberg, Hans-Christian; Hadji, Peyman; Tesch, Hans; Häberle, Lothar; Ettl, Johannes; Lux, Michael P; Lüftner, Diana; Wallwiener, Markus; Müller, Volkmar; Beckmann, Matthias W; Belleville, Erik; Wimberger, Pauline; Hielscher, Carsten; Geberth, Matthias; Fersis, Nikos; Abenhardt, Wolfgang; Kurbacher, Christian; Wuerstlein, Rachel; Thomssen, Christoph; Untch, Michael; Fasching, Peter A; Janni, Wolfgang; Fehm, Tanja N; Wallwiener, Diethelm; Brucker, Sara Y; Schneeweiss, Andreas.

In: BREAST, Vol. 37, 02.2018, p. 42-51.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Hartkopf, AD, Huober, J, Volz, B, Nabieva, N, Taran, F-A, Schwitulla, J, Overkamp, F, Kolberg, H-C, Hadji, P, Tesch, H, Häberle, L, Ettl, J, Lux, MP, Lüftner, D, Wallwiener, M, Müller, V, Beckmann, MW, Belleville, E, Wimberger, P, Hielscher, C, Geberth, M, Fersis, N, Abenhardt, W, Kurbacher, C, Wuerstlein, R, Thomssen, C, Untch, M, Fasching, PA, Janni, W, Fehm, TN, Wallwiener, D, Brucker, SY & Schneeweiss, A 2018, 'Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry', BREAST, vol. 37, pp. 42-51. https://doi.org/10.1016/j.breast.2017.10.002

APA

Hartkopf, A. D., Huober, J., Volz, B., Nabieva, N., Taran, F-A., Schwitulla, J., Overkamp, F., Kolberg, H-C., Hadji, P., Tesch, H., Häberle, L., Ettl, J., Lux, M. P., Lüftner, D., Wallwiener, M., Müller, V., Beckmann, M. W., Belleville, E., Wimberger, P., ... Schneeweiss, A. (2018). Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry. BREAST, 37, 42-51. https://doi.org/10.1016/j.breast.2017.10.002

Vancouver

Hartkopf AD, Huober J, Volz B, Nabieva N, Taran F-A, Schwitulla J et al. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry. BREAST. 2018 Feb;37:42-51. https://doi.org/10.1016/j.breast.2017.10.002

Bibtex

@article{5c3b3d2384404d899c0a4d2283546066,
title = "Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry",
abstract = "PURPOSE: This study describes comprehensive data from a breast cancer registry concerning the use of endocrine treatment (ET) and chemotherapy in the first, second and higher therapy lines in hormone receptor (HR) positive, HER2 negative metastatic breast cancer (MBC).METHODS: The PRAEGNANT study is a real-time registry for patients with MBC. Therapies were categorized into the following categories: chemotherapy, aromatase inhibitor (AI), tamoxifen, fulvestrant, or everolimus plus ET and reported for first, second and third line or higher therapy use. Also treatment sequences for the first, second and third therapy line were analyzed.RESULTS: This analysis includes 958 patients with HR positive, HER2 negative MBC. 42.7% were treated with a chemotherapy in the first therapy line compared to 45.9% receiving an ET. A total of 25.9% were treated with everolimus plus anti-hormone therapy in any therapy line. 34.1% were treated with fulvestrant as single agent therapy. Analyzing therapy sequences, the administration of three different chemotherapies in a row was the most frequently used pattern.CONCLUSIONS: This analysis shows that across all three first therapy lines chemotherapy is a dominant therapy for HR positive, HER2 negative MBC patients. Education about the efficacy of ET might help to increase its use and decrease the possible burden of chemotherapy related toxicities.",
keywords = "Journal Article",
author = "Hartkopf, {Andreas D} and Jens Huober and Bernhard Volz and Naiba Nabieva and Florin-Andrei Taran and Judith Schwitulla and Friedrich Overkamp and Hans-Christian Kolberg and Peyman Hadji and Hans Tesch and Lothar H{\"a}berle and Johannes Ettl and Lux, {Michael P} and Diana L{\"u}ftner and Markus Wallwiener and Volkmar M{\"u}ller and Beckmann, {Matthias W} and Erik Belleville and Pauline Wimberger and Carsten Hielscher and Matthias Geberth and Nikos Fersis and Wolfgang Abenhardt and Christian Kurbacher and Rachel Wuerstlein and Christoph Thomssen and Michael Untch and Fasching, {Peter A} and Wolfgang Janni and Fehm, {Tanja N} and Diethelm Wallwiener and Brucker, {Sara Y} and Andreas Schneeweiss",
note = "Copyright {\textcopyright} 2017 Elsevier Ltd. All rights reserved.",
year = "2018",
month = feb,
doi = "10.1016/j.breast.2017.10.002",
language = "English",
volume = "37",
pages = "42--51",
journal = "BREAST",
issn = "0960-9776",
publisher = "Churchill Livingstone",

}

RIS

TY - JOUR

T1 - Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry

AU - Hartkopf, Andreas D

AU - Huober, Jens

AU - Volz, Bernhard

AU - Nabieva, Naiba

AU - Taran, Florin-Andrei

AU - Schwitulla, Judith

AU - Overkamp, Friedrich

AU - Kolberg, Hans-Christian

AU - Hadji, Peyman

AU - Tesch, Hans

AU - Häberle, Lothar

AU - Ettl, Johannes

AU - Lux, Michael P

AU - Lüftner, Diana

AU - Wallwiener, Markus

AU - Müller, Volkmar

AU - Beckmann, Matthias W

AU - Belleville, Erik

AU - Wimberger, Pauline

AU - Hielscher, Carsten

AU - Geberth, Matthias

AU - Fersis, Nikos

AU - Abenhardt, Wolfgang

AU - Kurbacher, Christian

AU - Wuerstlein, Rachel

AU - Thomssen, Christoph

AU - Untch, Michael

AU - Fasching, Peter A

AU - Janni, Wolfgang

AU - Fehm, Tanja N

AU - Wallwiener, Diethelm

AU - Brucker, Sara Y

AU - Schneeweiss, Andreas

N1 - Copyright © 2017 Elsevier Ltd. All rights reserved.

PY - 2018/2

Y1 - 2018/2

N2 - PURPOSE: This study describes comprehensive data from a breast cancer registry concerning the use of endocrine treatment (ET) and chemotherapy in the first, second and higher therapy lines in hormone receptor (HR) positive, HER2 negative metastatic breast cancer (MBC).METHODS: The PRAEGNANT study is a real-time registry for patients with MBC. Therapies were categorized into the following categories: chemotherapy, aromatase inhibitor (AI), tamoxifen, fulvestrant, or everolimus plus ET and reported for first, second and third line or higher therapy use. Also treatment sequences for the first, second and third therapy line were analyzed.RESULTS: This analysis includes 958 patients with HR positive, HER2 negative MBC. 42.7% were treated with a chemotherapy in the first therapy line compared to 45.9% receiving an ET. A total of 25.9% were treated with everolimus plus anti-hormone therapy in any therapy line. 34.1% were treated with fulvestrant as single agent therapy. Analyzing therapy sequences, the administration of three different chemotherapies in a row was the most frequently used pattern.CONCLUSIONS: This analysis shows that across all three first therapy lines chemotherapy is a dominant therapy for HR positive, HER2 negative MBC patients. Education about the efficacy of ET might help to increase its use and decrease the possible burden of chemotherapy related toxicities.

AB - PURPOSE: This study describes comprehensive data from a breast cancer registry concerning the use of endocrine treatment (ET) and chemotherapy in the first, second and higher therapy lines in hormone receptor (HR) positive, HER2 negative metastatic breast cancer (MBC).METHODS: The PRAEGNANT study is a real-time registry for patients with MBC. Therapies were categorized into the following categories: chemotherapy, aromatase inhibitor (AI), tamoxifen, fulvestrant, or everolimus plus ET and reported for first, second and third line or higher therapy use. Also treatment sequences for the first, second and third therapy line were analyzed.RESULTS: This analysis includes 958 patients with HR positive, HER2 negative MBC. 42.7% were treated with a chemotherapy in the first therapy line compared to 45.9% receiving an ET. A total of 25.9% were treated with everolimus plus anti-hormone therapy in any therapy line. 34.1% were treated with fulvestrant as single agent therapy. Analyzing therapy sequences, the administration of three different chemotherapies in a row was the most frequently used pattern.CONCLUSIONS: This analysis shows that across all three first therapy lines chemotherapy is a dominant therapy for HR positive, HER2 negative MBC patients. Education about the efficacy of ET might help to increase its use and decrease the possible burden of chemotherapy related toxicities.

KW - Journal Article

U2 - 10.1016/j.breast.2017.10.002

DO - 10.1016/j.breast.2017.10.002

M3 - SCORING: Journal article

C2 - 29100043

VL - 37

SP - 42

EP - 51

JO - BREAST

JF - BREAST

SN - 0960-9776

ER -